JPWO2020233655A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020233655A5 JPWO2020233655A5 JP2021569135A JP2021569135A JPWO2020233655A5 JP WO2020233655 A5 JPWO2020233655 A5 JP WO2020233655A5 JP 2021569135 A JP2021569135 A JP 2021569135A JP 2021569135 A JP2021569135 A JP 2021569135A JP WO2020233655 A5 JPWO2020233655 A5 JP WO2020233655A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- nucleotides
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910431319.2 | 2019-05-22 | ||
| CN201910431319 | 2019-05-22 | ||
| CN201910433243 | 2019-05-23 | ||
| CN201910433243.7 | 2019-05-23 | ||
| PCT/CN2020/091489 WO2020233655A1 (zh) | 2019-05-22 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533841A JP2022533841A (ja) | 2022-07-26 |
| JPWO2020233655A5 true JPWO2020233655A5 (zh) | 2023-05-31 |
Family
ID=73458363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569135A Pending JP2022533841A (ja) | 2019-05-22 | 2020-05-21 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230313195A1 (zh) |
| EP (1) | EP3974530A4 (zh) |
| JP (1) | JP2022533841A (zh) |
| KR (1) | KR20220011656A (zh) |
| CN (2) | CN117701564A (zh) |
| AU (1) | AU2020280439A1 (zh) |
| CA (1) | CA3141372A1 (zh) |
| TW (1) | TW202111118A (zh) |
| WO (1) | WO2020233655A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023017004A1 (en) * | 2021-08-09 | 2023-02-16 | Cargene Therapeutics Pte. Ltd. | Inhibitory nucleic acids for pcsk9 |
| TW202342747A (zh) * | 2021-12-03 | 2023-11-01 | 大陸商中天（上海）生物科技有限公司 | 具有高穩定性和基因沉默活性的小干擾rna分子的修飾模式 |
| TW202334425A (zh) * | 2021-12-16 | 2023-09-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種ｄｓｒｎａ、其製備方法及應用 |
| WO2023109945A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其制备方法及应用 |
| WO2023134609A1 (zh) * | 2022-01-13 | 2023-07-20 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制PCSK9基因表达的RNAi剂及其应用 |
| WO2023241591A1 (zh) * | 2022-06-14 | 2023-12-21 | 大睿生物医药科技(上海)有限公司 | 调控PCSK9基因活性的siRNA分子 |
| CN118086311A (zh) * | 2023-05-25 | 2024-05-28 | 苏州时安生物技术有限公司 | 抑制PCSK9基因表达的siRNA、其缀合物和药物组合物及用途 |
| CN117563009A (zh) * | 2023-09-01 | 2024-02-20 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011431A2 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
| CA2677068A1 (en) * | 2009-09-01 | 2011-03-01 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2011028938A1 (en) * | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| DK2640700T3 (en) | 2010-11-15 | 2019-01-14 | Life Technologies Corp | AMINOUS TRANSFECTION REAGENTS AND METHODS FOR PREPARING USE THEREOF |
| AR090905A1 (es) * | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| JP2015525797A (ja) | 2012-08-06 | 2015-09-07 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 糖質コンジュゲートｒｎａ剤およびその調製方法 |
| HUE035887T2 (en) * | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
| PT2992098T (pt) | 2013-05-01 | 2019-07-05 | Ionis Pharmaceuticals Inc | Composições e métodos para modular a expressão de hbv e ttr |
| DK3019200T3 (da) * | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
| KR102494171B1 (ko) * | 2014-08-20 | 2023-02-02 | 알닐람 파마슈티칼스 인코포레이티드 | 변형 이중-가닥 rna 제제 |
| EA201890571A1 (ru) * | 2015-08-25 | 2018-10-31 | Элнилэм Фармасьютикалз, Инк. | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) |
| KR20190058477A (ko) * | 2016-08-17 | 2019-05-29 | 솔스티스 바이올로직스, 리미티드 | 폴리뉴클레오티드 구축물 |
| MX2019004573A (es) * | 2016-10-18 | 2019-10-07 | The Medicines Co | Metodos para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9). |
| BR112019021359A2 (pt) * | 2017-04-11 | 2020-05-05 | Arbutus Biopharma Corp | moléculas, composições, compostos, métodos para administrar um sirna, para preparar um composto e para tratar uma infecção, composto ou sal, conjugado de galnac e uso de um composto |
-
2020
- 2020-05-21 TW TW109116933A patent/TW202111118A/zh unknown
- 2020-05-21 US US17/595,584 patent/US20230313195A1/en active Pending
- 2020-05-21 KR KR1020217040159A patent/KR20220011656A/ko unknown
- 2020-05-21 CN CN202311628556.0A patent/CN117701564A/zh active Pending
- 2020-05-21 CA CA3141372A patent/CA3141372A1/en active Pending
- 2020-05-21 JP JP2021569135A patent/JP2022533841A/ja active Pending
- 2020-05-21 WO PCT/CN2020/091489 patent/WO2020233655A1/zh active Search and Examination
- 2020-05-21 CN CN202080007281.7A patent/CN113286888B/zh active Active
- 2020-05-21 EP EP20809702.2A patent/EP3974530A4/en active Pending
- 2020-05-21 AU AU2020280439A patent/AU2020280439A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503929A5 (zh) | ||
| JP2021503940A5 (zh) | ||
| JP6649248B2 (ja) | 細胞取り込みの向上のための化合物および方法 | |
| JP2021502120A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| JP2021503930A5 (zh) | ||
| JP2021500025A5 (zh) | ||
| KR20150110562A (ko) | Ｌｎａ 올리고뉴클레오타이드 탄수화물 컨쥬게이트 | |
| JP2022507282A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| EP4073252A1 (en) | Rnai constructs and methods for inhibiting lpa expression | |
| EP3861118A1 (en) | Modified oligomeric compounds and uses thereof | |
| JPWO2018003739A1 (ja) | 機能的リガンドを含む核酸複合体 | |
| CN113454221A (zh) | 含有三元环的双链核酸抑制剂分子 | |
| JPWO2019105414A5 (zh) | ||
| JPWO2020233655A5 (zh) | ||
| KR20220004675A (ko) | 단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자 | |
| JPWO2019105435A5 (zh) | ||
| JPWO2020238763A5 (zh) | ||
| CN116769780A (zh) | 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途 | |
| JPWO2020063198A5 (zh) | ||
| JPWO2020233650A5 (zh) | ||
| RU2021130599A (ru) | Нуклеиновая кислота, фармацевтическая композиция, конъюгат, способ получения и применение | |
| JPWO2020198509A5 (zh) | ||
| JPWO2020233651A5 (zh) | ||
| RU2021134268A (ru) | Нуклеиновая кислота, фармацевтическая композиция и конъюгат, способ получения и применение | |
| RU2021130601A (ru) | Нуклеиновая кислота, фармацевтическая композиция, конъюгат, способ получения и применение |